U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB


[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
     OF 1934

     For the quarterly period ended September 30, 2005.

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
     OF 1934

                        COMMISSION FILE NUMBER: 000-28519

                                   ZANN CORP.
                 (Name of small business issuer in its charter)

                     NEVADA                                 76-0510754
        (State or other jurisdiction of                  (I.R.S. Employer
         incorporation or organization)                 Identification No.)

1549 N. LEROY ST., SUITE D-200, FENTON, MICHIGAN               48430
    (Address of principal executive offices)                 (Zip Code)

                                 (810) 714-2978
                           (Issuer's telephone number)


     Check  whether  the issuer (1) filed all reports required to be filed by
Section 13  or  15(d) of the Exchange Act during the past 12 months (or for such
shorter period  that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes [X]
No [ ]

     State  the  number of shares outstanding of each of the issuer's classes of
common  equity,  as  of the latest practicable date: As of November 4, 2005, the
issuer  had  29,816,788  shares  of  its  common  stock  issued  and
outstanding.

     Transitional Small Business Disclosure Format (check one): Yes [ ]  No [X]


<PAGE>
<TABLE>
<CAPTION>
                                TABLE OF CONTENTS

<S>                                                                          <C>
PART I - FINANCIAL INFORMATION. . . . . . . . . . . . . . . . . . . . . . .   1
    Item 1.  Financial Statements (Unaudited) . . . . . . . . . . . . . . .   1
             Condensed Consolidated Balance Sheets. . . . . . . . . . . . .   1
             Condensed Consolidated Statement of Losses . . . . . . . . . .   2
             Condensed Consolidated Statements of Cash Flow . . . . . . . .   3
             Notes for Condensed Consolidated Financial Statements. . . . .   4
    Item 2.  Management's Discussion and Analysis or Plan of Operation. . .  14
    Item 3.  Controls and Procedures. . . . . . . . . . . . . . . . . . . .  18
PART II - OTHER INFORMATION . . . . . . . . . . . . . . . . . . . . . . . .  19
    Item 1.  Legal Proceedings. . . . . . . . . . . . . . . . . . . . . . .  19
    Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds. .  19
    Item 3.  Defaults Upon Senior Securities .. . . . . . . . . . . . . . .  20
    Item 4.  Submission of Matters to a Vote of Security Holders. . . . . .  20
    Item 5.  Other Information. . . . . . . . . . . . . . . . . . . . . . .  20
    Item 6.  Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
SIGNATURES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</TABLE>


<PAGE>
<TABLE>
<CAPTION>
                                           PART I - FINANCIAL INFORMATION

ITEM 1.   FINANCIAL STATEMENTS.
                                                     ZANN CORP.
                                       CONDENSED CONSOLIDATED BALANCE SHEETS


                                                                           September 30, 2005    December 31, 2004
                                                                              (Unaudited)
                                                                              -----------
<S>                                                                       <C>                   <C>
ASSETS
------
Current Assets
    Cash and cash equivalents                                             $            25,411   $           39,890
    Inventory (Note D)                                                                103,475               16,397
    Prepaid expenses and other                                                            316                2,314
                                                                          -----------------------------------------
        Total Current Assets                                                          129,202               58,601
                                                                          -----------------------------------------

Property and equipment, net of depreciation of $151,825                             2,446,262                    -
                                                                          -----------------------------------------
Intangibles                                                                         2,587,640                    -
                                                                          -----------------------------------------
        Total Assets                                                      $         5,163,104   $           58,601
                                                                          =========================================

LIABILITIES AND DEFICIENCY IN STOCKHOLDERS' EQUITY
--------------------------------------------------
Current Liabilities
    Accounts payable and accrued liabilities (Note E)                     $         1,009,425   $          704,934
    Accounts payable - related party (Note I)                                         196,585                1,600
    Notes payable - others (Note F)                                                 4,689,475               30,000
                                                                          -----------------------------------------
        Total Current Liabilities                                                   5,895,485              736,534
                                                                          -----------------------------------------

Notes payable - long term                                                             293,855                    -
                                                                          -----------------------------------------
        Total Liabilities                                                           6,189,340              736,534
                                                                          -----------------------------------------

Commitment and contingencies (Note M)                                                       -                    -
Deficiency in Stockholders' Equity
    Common stock, $.001 par value, 4,000,000,000 shares authorized,
29,816,788 and 219,800 shares outstanding at September 30, 2005 and
December 31, 2004 respectively                                            $            29,817   $              220
    Subscription receivable                                                          (150,000)             (39,616)
    Preferred stock, $.001 par value, 350,000,000 shares authorized
        Series A: 2,497,700 and 2,437,700 shares issued and outstanding
at September 30, 2005 and December 31, 2004 respectively                                2,498                2,438
        Series B:  392,501 and 0 shares issued and outstanding at
September 30, 2005 and December 31, 2004 respectively                                     393                    -
        Series C: 10,000,000 issued and outstanding at September 30,
2005 and December 31, 2004 respectively                                                10,000               10,000
Additional paid-in-capital                                                         37,060,946           35,468,653
Accumulated deficit                                                               (37,979,890)         (36,119,628)
                                                                          -----------------------------------------
        Total Deficiency in Stockholders' Equity                                   (1,026,236)            (677,933)
                                                                          -----------------------------------------
Total Liabilities and Deficiency in Stockholders' Equity                  $         5,163,104   $           58,601
                                                                          =========================================
</TABLE>

See accompanying notes to unaudited condensed consolidated financial statements


                                      - 1 -
<PAGE>
<TABLE>
<CAPTION>
                                                         ZANN CORP.
                                       CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                                         (UNAUDITED)


                                                             For the three months               For the nine months
                                                              ended September 30                 ended September 30
                                                            2005              2004             2005              2004
                                                                       (Restated-Note J)                  (Restated-Note J)
                                                        --------------------------------------------------------------------
<S>                                                     <C>            <C>                 <C>            <C>
REVENUES
Sales, net                                              $        227   $             505   $        826   $             505
Cost of goods sold                                              (126)                  -         (1,242)                  -
                                                        --------------------------------------------------------------------
    Gross (loss)                                                 101                 505           (417)                505
                                                        --------------------------------------------------------------------
OPERATING EXPENSES
    Depreciation                                             66,526                   -         66,526                   -
    Selling, general and administrative                      472,539           3,652,015      1,783,362           5,639,283
                                                        --------------------------------------------------------------------
Total operating expenses                                     539,065           3,652,015      1,849,888           5,639,283
                                                        --------------------------------------------------------------------
LOSS FROM OPERATIONS                                        (538,964)         (3,651,510)    (1,850,305)         (5,638,778)
                                                        --------------------------------------------------------------------

Other (expense) income
    Interest income (expense)                                 (5,517)            (12,835)        (9,956)            (12,835)
    Goodwill write off                                             -            (296,280)             -            (296,280)
    Debt forgiveness                                               -                                  -             616,132
                                                        --------------------------------------------------------------------
        Total other (expense) income                          (5,517)           (309,115)        (9,956)            307,017
                                                        --------------------------------------------------------------------
NET (LOSS) BEFORE PROVISION FOR INCOME
TAX AND MINORITY INTEREST                                   (544,480)         (3,960,625)    (1,860,260)         (5,331,761)
PROVISION FOR INCOME TAX                                           -                   -              -                   -
                                                        --------------------------------------------------------------------
NET (LOSS)                                              $   (544,480)  $      (3,960,625)  $ (1,860,260)  $      (5,331,761)
                                                        ====================================================================
Loss per share (basic and fully diluted)                $      (0.02)  $         (800.77)  $      (0.11)  $       (1,273.71)
                                                        ====================================================================
Basic and diluted weighted average number of shares
outstanding as restated for reverse and forward stock
splits                                                    27,163,363               4,946     17,165,635               4,186
                                                        ====================================================================
</TABLE>

 See accompanying notes to unaudited condensed consolidated financial statements


                                      - 2 -
<PAGE>
<TABLE>
<CAPTION>
                                                 ZANN CORP.
                               CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW
                                                (UNAUDITED)


                                                                  For the nine months ended September 30
                                                                       2005                    2004
                                                              ---------------------------------------------
<S>                                                           <C>                      <C>
Cash Flows Used in Operating Activities                                                 (Restated - Note J)
    Net (loss)                                                $           (1,860,261)  $        (5,331,761)
    Adjustments to reconcile net loss
    to net cash used in operating activities:
        Depreciation expense                                                  66,526                     -
        Common stock issued for services                                     486,041             3,391,233
        Employee stock option expense                                        512,326               558,117
        Preferred series A issued for services                                   900                     -
        Preferred series B issued for services and interest                    1,485                     -
        Goodwill write off                                                         -               296,280
        Debt forgiven                                                              -              (616,132)
    Changes in:
        Accounts payable and accrued expenses                                341,431              (175,876)
        Inventory and prepaid expenses                                         3,677                  (785)
        Accounts payable - related                                                 -                (9,548)
                                                              ---------------------------------------------
Net cash provided (used) in operating activities                            (447,874)           (1,888,472)
                                                              ---------------------------------------------

Cash Flows from Investing Activities
    Cash acquired in acquisition of subsidiary                                   395                     -
    Acquisition of subsidiary                                               (200,000)                    -
    Increase in other assets                                                       -               (12,400)
                                                              ---------------------------------------------
Net cash (used) in investing activities                                     (199,605)              (12,400)
                                                              ---------------------------------------------
Cash Flows from Financing Activities:
    Proceeds from sale of common stock                                       357,906             1,524,746
    Proceeds from sale of preferred stock                                    117,001                     -
    Convertible debenture                                                    100,000                     -
    Payments on convertible debenture                                         (1,907)                    -
    Notes payable                                                            225,000                     -
    Payments on notes payable                                               (165,000)                    -
    Proceeds from related party                                                    -               113,750
    Repayment of note payable to related party                                     -               (90,000)
                                                              ---------------------------------------------
Net cash provided  by financing activities                                   633,000             1,548,496
                                                              ---------------------------------------------

Net change in cash                                                           (14,479)             (352,376)
Cash at beginning of period                                                   39,890               367,978
                                                              ---------------------------------------------
Cash at end of period                                         $               25,411   $            15,602
                                                              =============================================

Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for interest                      $                9,956   $            12,835
Cash paid during the period for income taxes                                       -                     -
Common stock issued in exchange for services rendered         $              486,041   $         3,391,233
Preferred B shares issued for cash received in October 2005   $              150,000                     -
Preferred A and B shares issued for services and interest     $                2,385                     -
Preferred shares issued for debt                                                   -   $         3,022,550
Employee stock option expense                                 $              512,326   $           558,117
Income from liabilities forgiven                                                   -   $           616,132
Acquisition: (Note B and C)
    Assets acquired                                           $             5,189581   $                 -
    Liabilities assumed                                       $              509,581   $                 -
    Cash paid                                                 $              200,000   $                 -
    Notes payable                                             $            4,480,000   $                 -
</TABLE>

 See accompanying notes to unaudited condensed consolidated Financial Statements


                                      - 3 -
<PAGE>
                                   ZANN CORP.
         NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

                               SEPTEMBER 30, 2005


NOTE A  -  SUMMARY OF ACCOUNTING POLICIES

GENERAL

The accompanying unaudited condensed consolidated financial statements have been
prepared  in  accordance  with  accounting  principles generally accepted in the
United  States  of  America  for  interim  financial  information  and  with the
instructions  to  Form  10-QSB.  Accordingly,  they  do  not  include all of the
information  and  footnotes required by generally accepted accounting principles
for  complete  financial  statements.

In  the  opinion  of management, all adjustments (consisting of normal recurring
accruals)  considered  necessary  for  a  fair  presentation have been included.
Accordingly,  the  results  from  operations  for  the  nine-month  period ended
September  30,  2005  are  not necessarily indicative of the results that may be
expected  for  the  year  ending  December  31,  2005.  The  unaudited condensed
consolidated  financial  statements  should  be  read  in  conjunction  with the
consolidated  December  31,  2004  financial  statements  and  footnotes thereto
included  in  the  Company's  SEC  Form  10-KSB.

BUSINESS AND BASIS OF PRESENTATION

The  Company  incorporated  in  Florida on March 4, 1999 as Investra Enterprises
Inc.  On  March  6,  2000,  we  completed  a  Share  Purchase Agreement in which
Pathobiotek  Diagnostics,  Inc.,  a  Texas  Corporation,  acquired  all  of  our
issued  and  outstanding  shares  for  $150,000  for the purpose of completing a
merger  of  Pathobiotek  Diagnostics, Inc. and Investra Enterprises. Pathobiotek
Diagnostics, Inc., a Texas corporation, was the surviving entity.

Effective  September 7, 2001, we implemented a reverse split of our Common Stock
at  the  ratio  of  one  post-consolidation  share for each 40 pre-consolidation
shares, except that no shareholder was reduced to less than 10 shares.

On  October  16,  2001, we completed the Plan and Agreement of Reorganization by
and  between  Pathobiotek  Diagnostics  Inc.,  ATNG  Acquisition,  Inc., a Texas
corporation,  and  ATNG,  Inc.,  a  Nevada  corporation  under which Pathobiotek
Diagnostics  Inc.  issued 27,836,186 shares of its common stock as consideration
for  its  wholly owned subsidiary, ATNG Acquisition, Inc. to acquire 100 percent
of the issued and outstanding stock of ATNG, Inc., a Nevada corporation.

Following  the October 16, 2001 reorganization, ATNG Acquisition, Inc. and ATNG,
Inc. merged. On October 17, 2001, we changed our name to ATNG, Inc. On September
6,  2003  we  changed  our domicile from Texas to Nevada and changed our name to
ATNG  Inc.

On August 10, 2004, the Company acquired Blue Kiwi, Inc., a Michigan corporation
engaged  in  the  marketing and sale of nutritional supplements. Blue Kiwi, Inc.
currently markets two lines of products: Fatigue Pack(R) and PMS(TM) Pack.

In  November,  2004,  the  Shareholders  and Directors of the Company approved a
change  in  the  name  of the Company from ATNG, Inc. to Zann Corp., amended its
Articles  of  Incorporation,  increasing  the  number  of  authorized  shares to
4,000,000,000,  and  authorized a reverse stock split effective December 3, 2004
of one post consolidation share for every 900 pre-consolidation share.

On  March  1, 2005,  the  sole  Director  approved  a  decrease  in  the  number
of  authorized  shares  to  11,428,572  and  authorized  a  reverse  stock split
effective  March  10,  2005  of  one post  consolidation  share  for  every  350
pre-consolidation  shares.

On  April  19,  2005  the  Sole Director approved a forward stock split of three
shares  for  every  one  share  held  as  of  May  3, 2005.  On May 9, 2005, the
shareholders  and directors of the Company amended its Articles of Incorporation
to  increase  the  authorized  Common  Stock to 4,000,000,000 and the authorized
Preferred  Stock  to  350,000,000.


                                      - 4 -
<PAGE>
The  accompanying financial statements reflect these changes.  Accordingly,  all
historical  weighted  average  share and  per  share  amounts have been restated
to  reflect  the  reverse  and  forward  stock  splits.

On  June  27,  2005  the  Company acquired approximately 42.6% of the Common and
6.52%  of  the Convertible Preferred Second Series of Sartam Industries, Inc., a
Florida  Corporation  engaged  the  manufacturing and sale of automatic riveting
machines  and  the  re-supply of riveting belts. We are presently evaluating the
assets  of  Sartam  Industries,  Inc.  The  condensed  consolidated  financial
statements  include  the  estimated fair market value of the assets acquired and
the related notes payable and an insignificant amount of operating expenses.

The  condensed  consolidated  financial  statements  include the accounts of the
Company,  Blue  Kiwi,  Inc.,  the  Company's wholly-owned subsidiary, and Sartam
Industries,  Inc., a subsidiary of which the Company owns approximately 42.6% of
the  Common  Stock  and  6.52%  of  the  Convertible  Preferred  Second  Series.
Significant  intercompany  transactions  have  been eliminated in consolidation.

INVENTORY

The  Company  values  inventory  on  the first in, first out basis. Inventory is
reviewed  periodically  for obsolescence and any unsaleable products are written
off.  Health  and  nutritional  supplements  are  purchased  from  an  outside
manufacturer  and include all costs including labeling and packaging. Rivet guns
and  magazines  are  manufactured  and  include  all  direct  and indirect costs
associated  with  the  manufacturing.

PROPERTY  AND  EQUIPMENT

Costs  for  property  and  equipment  are  accumulated in work in progress until
assets  are  placed in service at which time the accumulated cost is depreciated
or  amortized  over  the  estimated  useful  life  of  the  asset.

Major  classes  of property and equipment on September 30, 2005 and December 31,
2004  consist  of  the  following:

<TABLE>
<CAPTION>
                                   2005       2004
                                --------------------
<S>                             <C>         <C>
Equipment                       $  129,005  $      -
Packaging Machines               2,469,082         -
                                --------------------
Gross Assets                     2,598,087         -
Less: Accumulated Depreciation     151,825         -
                                --------------------

Net Property and Equipment      $2,446,262  $      -
                                ====================
</TABLE>

Information  required  to  complete  the  purchase  price allocation for certain
tangible  and  intangible  property  relating to investment in Sartam is not yet
available.  Final  allocation of the purchase price will be completed as soon as
this  information  is  available.

IMPAIRMENT  OF  LONG-LIVED  ASSETS

The  Company  has  adopted  Statement  of Financial Accounting Standards No. 121
(SFAS  121).  The  Statement  requires  that  long-lived  assets  and  certain
identifiable intangibles held and used by the Company be reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of
an  asset  may  not  be  recoverable.  SFAS  No.  121 also requires assets to be
disposed  of  be  reported at the lower of the carrying amount or the fair value
less  costs  to  sell. Intangibles acquired in the acquisition of Sartam will be
accounted  for  according  to  SFAS  142.  Such  determination  will  be made by
management  subsequent  to  September  30,  2005.

SEGMENT  INFORMATION

The  Company  has  various  separate,  reportable  segments  under  Statement of
Financial  Accounting  Standards  No.  131,  Disclosures  about  Segments  of an
Enterprise  and Related Information ("SFAS 131"). SFAS establishes standards for
reporting  information  regarding  operating  segments  in  annual  financial
statements  and requires selected information for those segments to be presented
in  interim  financial reports issued to stockholders. SFAS 131 also establishes
standards  for  related  disclosures  about products and services and geographic
areas.  Operating  segments  are identified as components of an enterprise about
which separate discrete financial information is available for evaluation by the
chief  operating  decision  maker, or decision making group, in making decisions
how


                                      - 5 -
<PAGE>
to  allocate resources and assess performance. The information disclosed herein,
materially  represents all of the financial information related to the Company's
principal  operating  segments.

RECLASSIFICATIONS

Certain  reclassifications  have been made in prior periods financial statements
to  conform  to  classifications  used  in  the  current  period.

REVENUE  RECOGNITION

For  revenue  from  product  sales, the Company recognizes revenue in accordance
with  Staff  Accounting  Bulletin No. 104, REVENUE RECOGNITION ("SAB104"), which
superseded  Staff  Accounting Bulletin No. 101, REVENUE RECOGNITION IN FINANCIAL
STATEMENTS  ("SAB101").  SAB  101  requires that four basic criteria must be met
before  revenue  can  be  recognized:  (1) persuasive evidence of an arrangement
exists;  (2)  delivery  has  occurred;  (3)  the  selling  price  is  fixed  and
determinable;  and  (4)  collectibility  is reasonably assured. Determination of
criteria  (3)  and  (4)  are based on management's judgments regarding the fixed
nature of the selling prices of the products delivered and the collectibility of
those  amounts.  Provisions  for  discounts  and rebates to customers, estimated
returns  and  allowances,  and  other  adjustments  are provided for in the same
period  the related sales are recorded. The Company defers any revenue for which
the  product has not been delivered or is subject to refund until such time that
the  Company  and  the  customer  jointly  determine  that  the product has been
delivered  or  no  refund will be required. SAB 104 incorporates Emerging Issues
Task  Force 00-21 ("EITF 00-21") MULTIPLE-DELIVERABLE REVENUE ARRANGEMENTS. EITF
00-21  addresses  accounting  for  arrangements that may involve the delivery or
performance  of  multiple  products,  services  and/or rights to use assets. The
effect  of  implementing  EITF  00-21  on  the  Company's consolidated financial
position  and  results  of  operations  was  not  significant.  For  the  period
ended  September  30, 2005 neither of the Company's subsidiaries had significant
revenue.

Revenue  for  Sartam will be  recognized  when  finished  products  are  shipped
to the customer against confirmed purchase orders or contracts.

STOCK  BASED  COMPENSATION

In  December  2002,  the  FASB  issued SFAS No. 148, "Accounting for Stock-Based
Compensation-Transition and Disclosure-an amendment of SFAS 123." This statement
amends  SFAS  No.  123,  "Accounting  for  Stock-Based Compensation," to provide
alternative methods of transition for a voluntary change to the fair value based
method  of  accounting for stock-based employee compensation.  In addition, this
statement  amends  the  disclosure  requirements  of  SFAS  No.  123  to require
prominent  disclosures in both annual and interim financial statements about the
method of accounting for stock-based employee compensation and the effect of the
method  used on reported results.  The Company has chosen to continue to account
for  stock-based compensation using the intrinsic value method prescribed in APB
Opinion  No.  25 and related interpretations.  Accordingly, compensation expense
for stock options is measured as the excess, if any, of the fair market value of
the  Company's  stock  at  the  date of the grant over the exercise price of the
related option. The Company has adopted the annual disclosure provisions of SFAS
No.  148  in  its financial reports for the year ended December 31, 2003 and has
adopted  the  interim  disclosure  provisions  for its financial reports for the
subsequent periods. The Company does not have any awards of stock-based employee
compensation issued and outstanding at September 30, 2005.

On  December  16,  2004,  the Financial Accounting Standards Board (FASB) issued
FASB  Statement  No.  123R  (revised  2004),  "Share-Based  Payment"  which is a
revision  of  FASB Statement No. 123, "Accounting for Stock-Based Compensation".
Statement  123R  supersedes  APB opinion No. 25, "Accounting for Stock Issued to
Employees",  and  amends  FASB  Statement  No.  95,  "Statement  of Cash Flows".
Generally,  the  approach in Statement 123R is similar to the approach described
in  Statement  123. However, Statement 123R requires all share-based payments to
employees,  including  grants of employee stock options, to be recognized in the
income  statement  based on their fair values. Pro-forma disclosure is no longer
an  alternative.  On  April  14, 2005, the SEC amended the effective date of the
provisions  of  this  statement. The effect of this amendment by the SEC is that
the Company will have to comply with Statement 123R and use the Fair Value based
method of accounting no later than the first quarter of 2006. Management has not
determined  the  impact  that this statement will have on Company's consolidated
financial  statements.


                                      - 6 -
<PAGE>
NEW  ACCOUNTING  PRONOUNCEMENTS

In March 2005, the FASB issued FASB Interpretation (FIN) No. 47, "Accounting for
Conditional  Asset  Retirement  Obligations, an interpretation of FASB Statement
No.  143",  which requires an entity to recognize a liability for the fair value
of  a  conditional  asset retirement obligation when incurred if the liability's
fair  value  can  be  reasonably estimated. The Company is required to adopt the
provisions  of FIN 47 no later than its last quarter of fiscal 2006. The Company
does not expect the adoption of this Interpretation to have a material impact on
its consolidated financial position, results of operations or cash flows. In May
2005 the FASB issued Statement of Financial Accounting Standards (SFAS) No. 154,
"Accounting  Changes  and Error Corrections, a replacement of APB Opinion No. 20
and  FASB Statement No. 3." SFAS 154 requires retrospective application to prior
periods'  financial statements for changes in accounting principle, unless it is
impracticable  to determine either the period-specific effects or the cumulative
effect of the change. SFAS 154 also requires that retrospective application of a
change  in  accounting principle be limited to the direct effects of the change.
Indirect  effects  of  a  change  in  accounting  principle, such as a change in
non-discretionary  profit-sharing  payments resulting from an accounting change,
should  be  recognized  in  the  period  of the accounting change. SFAS 154 also
requires  that  a  change in depreciation, amortization, or depletion method for
long-lived,  non-financial  assets  be  accounted  for as a change in accounting
estimate effected by a change in accounting principle. SFAS 154 is effective for
accounting  changes  and  corrections  of  errors made in fiscal years beginning
after  December 15, 2005. Early adoption is permitted for accounting changes and
corrections  of  errors  made  in  fiscal  years  beginning  after the date this
Statement  is  issued.  The Company does not expect the adoption of this SFAS to
have  a  material  impact  on  its  consolidated  financial position, results of
operations  or  cash  flows.


NOTE B - MINORITY INTERESTS AND ACQUISITIONS

MINORITY INTERESTS
Minority  interest reflects the other owners' proportionate share in the assets,
liabilities and equity of business ventures as of the date of purchase, adjusted
by the proportionate share of post-acquisition income or loss.  As the operating
results  of entities with minority interest are consolidated, minority interests
income,  represents  the  income  or  loss  attributable  to  the  other owners.

ACQUISITIONS
On August 10, 2004, the Company acquired Blue Kiwi, Inc., a Michigan corporation
engaged  in  the  marketing  and  sale  of  nutritional supplements. The Company
entered  into  an  acquisition  agreement  with Robert C. Simpson, the Company's
president, chief executive officer, and majority shareholder, to purchase all of
the  issued  and  outstanding  capital  stock  of  Blue  Kiwi  Inc.,  a Michigan
corporation, for the sum of $5 million, payable in monthly installments of up to
10  percent of our gross profit. The obligation to pay $5 million to Dr. Simpson
in  connection  with the Blue Kiwi acquisition is expressly conditioned upon the
Company  generating  profit.  In  the  absence  of  profits,  the Company is not
obligated  to  pay $5 million to Dr.  Simpson.  The obligation will not bear any
interest.  As  of September 30, 2005, no payments have been made to Dr. Simpson.

As  a  result  of the acquisition, Blue Kiwi became our wholly-owned subsidiary.
The following  is  the  summary  of  assets  acquired  and  liabilities  assumed
and consideration paid relating to the transaction: assets acquired:

<TABLE>
<CAPTION>
<S>                        <C>
Cash                       $ 10,612
Other Current Assets          3,256
                           ---------
Total Assets Acquired        13,868
Accounts Payable              9,548
Due to Related Party        299,600
                           ---------
Total Liabilities Assumed   309,148
Cash Paid                    (1,000)
                           ---------
Goodwill                   $296,280
</TABLE>

The acquisition was accounted for as a purchase in accordance with SFAS 141 and,
accordingly, the operating results of the acquired company have been included in
the  Company's  consolidated financial statements since the date of acquisition.

On  June  27,  2005  the  Company acquired approximately 42.6% of the Common and
6.52%  of the Convertible Preferred Second Series of Sartam Industries, Inc. for
$200,000  in cash and $4,480,000 in Promissory Notes.  The acquisition of Sartam
was  accounted  for  using  the  purchase  method  in  accordance with SFAS 141,
"Business


                                      - 7 -
<PAGE>
Combinations".  The  results  of operations for Sartam have been included in the
condensed  consolidated statements of losses for the nine months ended September
30,  2005, since the date of acquisition. Sartam did not have any operations for
period  between  June  27,  2005  and  September  30,  2005.  Sartam  has  been
consolidated  based  on the significant percentage of ownership of common shares
(42.6%), control of the Board of Directors and management control of operations.
In  accordance  with  Financial  Accounting  Standard  (SFAS)  No. 141, Business
Combinations, the total purchase price was allocated to the estimated fair value
of  assets  acquired  and liabilities assumed. The estimate of fair value of the
assets  acquired  was  based on management's estimates. The total purchase price
was  allocated  to  the  assets  and  liabilities  acquired  as  follows:

<TABLE>
<CAPTION>
                              September 30, 2005    June 30, 2005
                             -------------------------------------
<S>                          <C>                   <C>
Assets acquired
Cash                         $               395   $          395
Inventory                                 88,757           89,027
Property and equipments-net            2,512,789        2,068,707
Intangibles                            2,587,640        2,764,263
                             -------------------------------------
                Total        $         5,189,581   $    4,922,392
                             =====================================
Liabilities assumed          $          (509,581)  $     (522,392)
Cash paid                               (200,000)        (200,000)
Notes payable                         (4,480,000)      (4,200,000)
                             -------------------------------------
                Total        $        (5,189,581)  $   (4,922,392
                             =====================================
</TABLE>

Amounts reported at June 30, 2005 differ from amounts at September 30, 2005 as a
result  of  additional  machinery and equipment located after acquisition and an
increase in Notes Payable to the selling shareholders for additional value.

Information  required  to  complete  the  purchase  price allocation for certain
tangible  and  intangible property is not yet available. Final allocation of the
purchase  price  will be completed as soon as this information is available. The
remaining  57.4% is owned by approximately 100 shareholders and is recognized as
minority  interest.  Sartam manufactures and sells patented Rivet Guns and Rivet
Belts  to  the  manufacturing  industry.  Operating  results  are  consolidated
consistent  with  the  acquisition  date  of June 27, 2005. There is no minority
interest reflected in the September 30, 2005 or December 31, 2004 balance sheets
because  Sartam  had  a  stockholders'  deficit  as  of  those  dates.

Sartam  Industries,  Inc.  has  two classes of preferred shares outstanding. The
First Series Preferred has a par value of $.01 per share, there are 7,000 shares
issued  and outstanding held by one individual. The shares have no voting right,
are not convertible into common, contain a $100 per share liquidation preference
and may be redeemed by the company for $100 per share five years after issuance.
The Second Series has a par value of $1.00 per share, there are 3,000,000 shares
authorized  and  2,563,278  shares  issued and outstanding at September 30, 2005
held  by  approximately 125 shareholders. The Second Series are convertible into
common  on  a  1:1 basis by the shareholders and may be converted into common by
the  Company after three years from issuance. The Second Series shareholders can
nominate  one  Director  to  the Board of Directors and are entitled to dividend
preference  of  60%  of  any  dividend  declared  by  the  Board  of  Directors.


NOTE C - GOODWILL AND OTHER INTANGIBLE ASSETS - ADOPTION OF SFAS 142

The  Company  has  adopted  Statement  of Financial Accounting Standards No. 142
"Goodwill  and  Other  Intangible Assets" (SFAS No. 142). SFAS No. 142 addresses
how  intangible  assets  that are acquired individually or with a group of other
assets  should  be accounted for in financial statements upon their acquisition.
This  statement  requires  goodwill amortization to cease and for goodwill to be
periodically  reviewed  for  impairment. Under SFAS No. 142, goodwill impairment
occurs  if  the  net  book  value of a reporting unit exceeds its estimated fair
value.  The Company's goodwill asset was with regard to the acquisitions of Blue
Kiwi  for $296,280. The test completed in the last quarter ended on December 31,
2004  indicated  that the recorded book value of the reporting unit exceeded its
fair  value,  as determined by discounted cash flows. The decrease in fair value
is  a  result  of:

     -    Significant operating losses during the past six months
     -    Unanticipated decline in revenues and profitability
     -    Loss of key personnel

As  a result of these events and circumstances, Company management believes that
the  fair  value  of  the  reporting  unit's goodwill has been reduced below its
carrying  value.  As  a  result,  management  performed  an  evaluation  of  the
reporting  unit's  tangible  and  intangible assets for purposes of  determining
the  implied  fair  value  of goodwill at December 31, 2004. Upon completion  of
the assessment, management recorded a non-cash impairment charge of  $(296,280),
net of tax, or $(23.16) per share, to reduce the carrying value of  goodwill  in
this  reporting  unit  to  its  estimated  value  of  $0.


                                      - 8 -
<PAGE>
The  Company  does not have complete information relating to intangible property
acquired  with  Sartam  acquisition.  The  Company  will  perform  allocation of
purchase  price, including intangibles and related impairment test subsequent to
September  30,  2005.

Considerable  management  judgment  is  necessary  to  estimate  fair  value.
Accordingly,  actual  results  could  vary  significantly  from  managements'
estimates.


NOTE  D  -  INVENTORIES

Inventories  are  stated  at  the  lower  of  cost  or  market determined by the
first-in, first-out (FIFO) method. As of September 30, 2005, inventories consist
of  pre-packaged  Health and Nutritional supplements of $14,718 and Manufactured
Rivet  Guns  and  Belts  of  $88,757  available  for  sale  to  customers.

Components  of inventories as of September 30, 2005 and December 31, 2004 are as
follows:

<TABLE>
<CAPTION>
                    2005     2004
                --------  -------
<S>             <C>       <C>
Finished goods  $103,475  $16,397
                ========  =======
</TABLE>

NOTE  E  -  ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts  payable  and accrued liabilities as of September 30, 2005 and December
31,  2004  consist  of  the  following:

<TABLE>
<CAPTION>
                        2005      2004
                  ----------  --------
<S>               <C>         <C>
Accounts payable  $  653,586  $346,801
Accrued salaries     120,909   116,903
Payroll taxes        234,930   234,930
Accrued interest           -     6,300
                  --------------------
Total             $1,009,425  $704,934
                  ====================
</TABLE>

NOTE  F  -  NOTES PAYABLE

Notes payable as of September 30, 2005 and December 31, 2004 are as follows:

<TABLE>
<CAPTION>
                                                                                    2005       2004
                                                                            -----------------------
<S>                                                                         <C>           <C>
Convertible Debenture, due April 1, 2005, interest 12%, convertible into
180,000 preferred shares-Series A. On April 1, 2005 the holder of this
debenture agreed to accept 50,000 shares of preferred shares-Series B.      $         -   $ 30,000
                                                                            -----------------------

Convertible Debenture, due January 1, 2006, interest 10%, payable
$1,000 per month, convertible into 15,000  preferred shares-Series A on
a basis of $.663 cents for each share converted                                  98,093          -
                                                                            -----------------------

Promissory Notes, Non-Interest Bearing, due  $620,000 in December
2005; $1,060,000 in March 2006 and $2,800,000 in August 2006                  4,480,000          -
                                                                            -----------------------

Promissory Note, Non-Interest Bearing, due in August 2005,
collateralized by 7,000 shares of Preferred Series A                             35,000          -
                                                                            -----------------------

Promissory Note, Non-Interest Bearing, due from royalties or revenue
from Honsel until paid in full.  If not paid from royalties or revenue
from Honsel then $50,000 due December 31, 2005 and remaining
balance due by December 31, 2006.                                               343,855          -
                                                                            -----------------------

Promissory Note dated July 1, 2001, Interest 9% per annum, due on
demand, including accrued interest of $382.50                                     1,382          -
                                                                            -----------------------


                                      - 9 -
<PAGE>
Promissory Note-Due December 31, 2005 plus interest at 10%                       25,000          -
                                                                            -----------------------

                                                       Total                  4,983,330     30,000
                                                                            =======================

Less: current portion                                                        (4,689,475)   (30,000)
                                                                            -----------------------

Notes payable-others-non current                                            $   293,855   $      -
                                                                            -----------------------
</TABLE>

NOTE  G  -  CAPITAL STOCK

In  November,  2004,  the  Shareholders  and Directors of the Company approved a
change  in  the  name  of the Company from ATNG, Inc. to Zann Corp., amended its
Articles  of  Incorporation,  increasing  the  number  of  authorized  shares to
4,000,000,000,  and  authorized a reverse stock split effective December 3, 2004
of  one  post  consolidation  share  for  every  900  pre-consolidation  share.

On  March  1, 2005,  the  sole  Director  approved  a  decrease  in  the  number
of  authorized  shares  to  11,428,572  and  authorized  a  reverse  stock split
effective  March  10,  2005  of  one post  consolidation  share  for  every  350
pre-consolidation  shares.

On  April  19,  2005  the  Sole Director approved a forward stock split of three
shares  for  every  one  share  held  as  of  May  3,  2005. On May 9, 2005, the
shareholders  and directors of the Company amended its Articles of Incorporation
to  increase  the  authorized  Common  Stock to 4,000,000,000 and the authorized
Preferred  Stock  to  350,000,000.

The  accompanying  financial  statements reflect these changes. Accordingly, all
historical  weighted  average  share and per share amounts have been restated to
reflect  the  reverse  and  forward  stock  splits.

COMMON STOCK

The  Company  is  authorized to issue 4,000,000,000 shares of common stock, with
$0.001  par  value per share. As of September 30, 2005 and December 31, 2004 the
Company has issued and outstanding 29,816,788 and 219,800 shares respectively of
common  stock  with  par  value  of  $0.001  per  share.

During  the nine months ended September 30, 2005 and 2004, the Company issued an
aggregate  of  14,192,327  and 1,980 shares for employee stock incentive program
for  $830,616 and $1,632,200 respectively. In relation to issuance of shares for
employee  stock  incentive  program,  the  Company received cash of $357,906 and
$1,524,746 respectively. The Company recorded $512,326 and $558,117 respectively
as  employee  compensation expenses for the nine months ended September 30, 2005
and  2004.

During  the nine months ended September 30, 2005 and 2004, the Company issued an
aggregate  of  14,965,062  and  383 shares respectively for various professional
services  valued  at  $486,041 and $607,395 respectively. The Company valued the
shares  issued  at  the  closing price on the date the shares were issued, which
approximated  the fair value of the services rendered. The compensation costs of
$486,041  and  $607,395  were charged to operations during the nine months ended
September  30,  2005  and  2004  respectively.

The  Company  accounts  for  its  employee  stock-based compensation plans under
Accounting  Principles Board ("APB") Opinion No. 25, Accounting for Stock Issued
to  Employees.  The  Company  granted  14,192,327  and 1,980 options to purchase
common stock to employees in the nine month periods ended September 30, 2005 and
2004,  respectively.  All options vest immediately, have an exercise price of 90
percent  of  market value on the date of grant and expire 10 years from the date
of  grant.  All options are exercised on the day of grant. At September 30, 2005
and  2004  the  Company  recorded $830,616 and $1,632,200 for the 14,192,327 and
1,980  shares issued to employees. The Company also charged expenses of $512,326
and  $558,117  relating  to  these  issuances.

All  of  the  above  share  information  has  been  adjusted to reflect the post
consolidation  of 900:1 on December 3, 2004 and  350:1  on  March  10,  2005 and
the  forward  split  of  3:1  on  May  3,  2005.


                                     - 10 -
<PAGE>
PREFERRED STOCK

Each  share  of Series A Preferred Stock is convertible into 10 shares of common
stock.  The Series A Preferred Stock will have one vote per share on all matters
submitted  to  a  vote  of  the  holders  of  common  stock,  including, without
limitation,  the election of directors.  At  September  30,  2005  and  December
31,  2004  there  were  2,497,700  and  2,437,700  shares  issued  and
outstanding,  respectively.

During the nine months ended September 30, 2004, the Company issued an aggregate
of  154,700  shares  of  Series  A  Preferred  Stock  in  exchange  of  debt for
$3,022,550.

During the nine months ended September 30, 2005, the Company issued an aggregate
of  60,000  shares of Series A Preferred Stock for various professional services
valued  at $900. The Company valued the shares issued at $0.015 per share, which
approximated  the fair value of the services rendered. The compensation costs of
$900 were charged to operations during the nine months ended September 30, 2005.

Each  share  of  Series  B Preferred Stock is convertible into 1 share of common
stock.  The Series B Preferred Stock will have one vote per share on all matters
submitted  to  a  vote  of  the  holders  of  common  stock,  including, without
limitation,  the  election of directors.  During the nine months ended September
30,  2005  the  Company  issued  392,501  shares  of Series B Preferred Stock as
follows:

<TABLE>
<CAPTION>
                                            Shares    Amount
                                            -------  --------
<S>                                         <C>      <C>
Convertible debenture and accrued interest   50,000  $ 36,300
Cash                                        267,001   267,001
Interest on promissory notes                 57,000     1,112
Services                                     18,500       372
                                            -------  --------
Total                                       392,501  $304,785
</TABLE>

During the period ended September 30, 2005 267,001 of Series B  Preferred Shares
were issued for cash of $267,001.  $117,001 was received before September 30 and
the  remaining  $150,000  was  received  in  October  2005.

At  September  30, 2005 and December 31, 2004 there were 392,501 and 0 shares of
Series  B  Preferred  Stock  issued  and  outstanding,  respectively.

The Series C Preferred Stock is not convertible into shares of common stock. The
Series  C  preferred stock has voting rights equal to 500 votes per share on all
matters  submitted  to  a  vote  of  the  holders of  common  stock,  including,
without  limitation,  the  election  of  directors.

At  September 30,  2005  and  December  31,  2004  there were 10,000,000  shares
of  Series  C  Preferred  Stock  issued  and  outstanding,  respectively.


NOTE H - NON-QUALIFIED STOCK COMPENSATION PLAN

In  May  2005, the Company authorized the Non-Employee Directors and Consultants
Retainer  Plan  ("NDCRP")  for  the  Year  2005.  The purpose of the NDRCP is to
attract  non-employee directors and consultants who are capable of improving the
success  of  the  Company  by  providing  a  direct economic interest to Company
performance.  Under the terms of the plan, non-employee directors or consultants
may  be compensated through the issuance of Company stock at Market Value on the
date  of issuance. The plan is administered by the Company's Board of Directors.


NOTE I - RELATED PARTY TRANSACTIONS

The  Company  advances  funds  to  related  entities  for  business  development
or  reimbursement  of  expenses.  During  nine  months ended September 30, 2005,
the  Company  has  reimbursed  $218,247 to related parties. The Company provides
management  and consulting services under agreements with entities controlled by
the  Company's  President.  The  Company's  management  has  determined that the
collectibility  and length of time to collect the amount due from these entities
can not be reasonably assured. Accordingly, revenues are recognized as collected
in connection with the services rendered. During the nine months ended September
30,  2005  and  2004,  the  Company  did  not  receive nor recognize revenues in
connection  with  providing  these  services.


                                     - 11 -
<PAGE>
At  September  30,  2005  and  December  31,  2004  the  Company  had  accounts
payable-related  party outstanding balances of $196,585 and $1,600 respectively.
These amounts represent funds advanced by an Officer for operating expenses.

During  the  nine  months ended September 30, 2005 and 2004 the employees of the
Company  were  paid  through   entities  owned by the Company's President. These
entities  are responsible for payroll, all payroll taxes, health insurance plans
and  all other employee benefits.  During  the nine  months ended  September 30,
2005  and  2004  the  Company  paid  these  entities  approximately $283,688 and
$354,169 respectively,  which  has  been charged to operations. At September 30,
2005,  $4,006  was owed to the related entity (included in accounts payable) for
payroll  expenses.  There  were no amounts due to these entities as of September
30,  2004.


NOTE J - RESTATEMENT

During the audit of the  Company's  financial  statements  for the twelve months
ended December 31, 2004,  the Company made accounting  adjustments  for  certain
transactions  that  occurred  during  the  nine  months ended September 30, 2004
as  follows:

-    Recorded  Employee  stock  options  at Fair Market Value at the date of the
     grant  less  cash  received  from the employee exercise. Increased Employee
     Stock  Option  expense by $514,563 and increased Additional Paid in Capital
     by $545,500 and increase stock subscription receivable by $30,937.
-    Recorded  Preferred  Series shares issued for debt at the fair market value
     of  the  shares  at  the  date  agreements were made with creditors to take
     shares  in  exchange  for their debts. The effect of this adjustment was to
     increase  the  Accumulated  Deficit  at  December  31,  2003 by $2,809,824,
     decrease  Debt  Forgiveness income by $285,641 and increase Additional Paid
     In Capital by $3,095,465 for the nine months ended September 30, 2004.
-    Adjusted  Other  Obligations  by  negotiating  the  cancellation of certain
     shares  to be issued to a related party and others. This adjustment reduced
     Debt  Forgiveness  by $135,600 and increasing Additional Paid in Capital by
     $135,600.
-    Adjusted  Common  Stock to reflect the 900:1 and 350:1 reverse stock splits
     on  December  3,  2004 and March 10, 2005, respectively and the 3:1 forward
     stock  split  on  May 3, 2005. This adjustment increased Additional Paid in
     Capital by $573,243 and decreased Common Stock by $573,243.
-    Adjusted  the  Par  Value  of Preferred Series C to reflect the correct par
     value.  This  adjustment decreased the Par Value of Series C by $10,000 and
     increased  Additional  Paid  in  Capital  by  $10,000.

The net effect of these adjustments for the nine months ended September 30, 2004
are as follows:

<TABLE>
<CAPTION>
                                                            Originally
Nine Months Ended September 30, 2004                         Reported      As Restated
                                                           ----------------------------
<S>                                                        <C>            <C>
Total assets                                               $     28,787   $     28,787
Liabilities and other obligations                               996,653        996,653
Common stock                                                    573,245              2
Common stock subscription receivable                                           (30,937)
Preferred series A                                                2,154          2,154
Preferred series C                                               20,000         10,000
Additional paid in capital                                   25,567,838     29,927,646
Accumulated deficit                                         (27,131,103)   (30,876,731)

Total liabilities and (deficiency) in stockholders equity        28,787         28,787

Net loss                                                     (4,375,894)    (5,331,761)
Loss per share-basic and diluted                                 (1,045)        (1,274)
</TABLE>

NOTE K - BUSINESS SEGMENTS

The Company reports its businesses as three reportable segments:


                                     - 12 -
<PAGE>
BUSINESS  DEVELOPMENT:  This segment provides management, financing and business
advice  to  other  business  units  and  subsidiaries  for  a  fee.

HEALTH  AND  NUTRITION  PRODUCTS:  This  segment  consists  of consumer products
designed  to  promote  good  health  and  wellness.

RIVET  TOOLS  AND MAGAZINES: This segment consists of manufactured products sold
to the manufacturing industry to improve the riveting process through the use of
the  Company's  patented  riveting  process.

Segment  operating income is total segment revenue reduced by operating expenses
identifiable  with  the  business  segment. Corporate includes general corporate
administrative  costs.

The  Company  evaluates performance and allocates resources based upon operating
income. The accounting policies of the reportable segments are the same as those
described  in  the  summary  of  accounting policies. There are no inter-segment
sales.  The  following  table summarizes segment asset and operating balances by
reportable  segment for the nine months ended September 30, 2005 and 2004:

<TABLE>
<CAPTION>
                                                 2005          2004
                                          --------------------------
<S>                                       <C>           <C>
Net Sales to External Customers:
    Health and nutrition products         $       826   $       505
                                          --------------------------
Total Sales to External Customers         $       826   $       505
                                          ==========================

Depreciation and Amortization:
    Business development                            -             -
    Health and nutrition products                   -             -
    Rivet guns and rivets                 $    66,526             -
                                          --------------------------
Total Depreciation and Amortization       $    66,526             -
                                          ==========================


General and Administrative Expense:
    Business development                  $ 1,749,778   $ 5,585,556
    Health and nutrition products              33,382        53,727
    Rivet guns and rivets                      66,728             -
                                          --------------------------
Total General and Administrative Expense  $ 1,849,888   $ 5,639,283
                                          ==========================

Capital Expenditures:
    Business development                            -             -
    Health and nutrition products                   -             -
    Rivet guns and rivets                           -             -
                                          --------------------------
Total Capital Expenditures                          -             -
                                          ==========================

Operating Loss:
    Business development                  $(1,758,338)  $(5,266,610)
    Health and nutrition products             (33,799)      (65,151)
    Rivet guns and rivets                     (68,124)            -
                                          --------------------------
Total Operating Loss                      $(1,860,261)  $(5,331,761)
                                          ==========================

Segment Assets:
    Business development                  $    21,981   $    14,979
    Health and nutrition products              18,272        13,808
    Rivet guns and rivets                   5,122,851             -
                                          --------------------------
Total Segment Assets                      $ 5,163,104   $    28,787
                                          ==========================
</TABLE>

NOTE L - GOING CONCERN

The  accompanying  statements have been prepared on a going concern basis, which
contemplates  the  realization  of assets and the satisfaction of liabilities in
the  normal course of business. As shown in the condensed consolidated financial
statements  during the nine months ended September 30, 2005 the Company incurred
a  loss  of  $1,860,261.  The Company's current liabilities exceeded its current
assets  by  $5,766,283  as  of  September  30,  2005.  These  factors


                                     - 13 -
<PAGE>
among others may indicate that the Company will be unable to continue as a going
concern  for  a  reasonable  period  of  time.

The  Company's  existence  is  dependent  upon  management's  ability to develop
profitable operations and resolve its liquidity problems. Management anticipates
the  Company will attain profitable status and improve its liquidity through the
continued  developing,  marketing  and  selling  of  its products and additional
equity  investment  in the Company. The accompanying financial statements do not
include  any  adjustments  that  might  result  should  the Company be unable to
continue  as  a  going  concern.

In  order  to  improve  the Company's liquidity, the Company is actively pursing
additional  financing  through  discussions  with investment bankers and private
investors.  There  can  be  no  assurance  the Company will be successful in its
effort  to  secure  additional  financing.

If  operations  and  cash  flows  continue  to  improve  through  these efforts,
management  believes  that  the  Company  can  continue  to operate. However, no
assurance  can  be  given  that  management's  actions will result in profitable
operations  or  the  resolution  of  its  liquidity  problems.


NOTE M - COMMITMENT AND CONTINGENCIES

The  Company  has formed a strategic alliance with Statewide Residential Lending
to originate residential mortgages throughout the State of Michigan. The Company
entered  into  an  agreement  to  manage  and  operate  several  Branches.

On  January 21, 2005, plaintiff Investrend Communications, Inc. d/b/a Investrend
Research  commenced an action via Verified Complaint in the Supreme Court of the
State of New York, County of Queens, against the Company. The complaint, through
three  causes  of  action, essentially alleged a breach of contract. The parties
have  executed an agreement to settle the matter for the total amount of $7,500,
to  be  paid in six (6) installments. The first installment was paid on November
9, 2005. The settlement amount has not been included in the financial statements
at  September  30,  2005.


ITEM 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS.

FORWARD-LOOKING INFORMATION

Much of the discussion in this Item is "forward looking" as that term is used in
Section 27A of the Securities Act and Section 21E of the Securities Exchange Act
of  1934.  Actual  operations  and  results  may  materially differ from present
plans  and  projections  due  to  changes  in  economic conditions, new business
opportunities,  changed  business  conditions,  and  other  developments.  Other
factors  that  could  cause  results  to  differ materially are described in our
filings  with  the  Securities  and  Exchange  Commission.

There  are  several  factors  that  could  cause  actual  results  or  events to
differ  materially  from  those anticipated, and include, but are not limited to
general  economic,  financial and business conditions, changes in and compliance
with  governmental  laws  and  regulations,  including various state and federal
environmental  regulations,  our  ability  to  obtain  additional financing from
outside  investors and/or bank and mezzanine lenders and our ability to generate
sufficient  revenues  to  cover  operating  losses  and  position  us to achieve
positive  cash  flow.

Readers  are  cautioned  not  to  place  undue  reliance  on the forward-looking
statements contained herein, which speak only as of the date hereof.  We believe
the  information  contained  in  this  Form 10-QSB to be accurate as of the date
hereof.  Changes  may  occur  after  that  date.   We  will  not  update  that
information  except  as  required  by  law  in  the  normal course of its public
disclosure  practices.

Additionally,  the  following  discussion  regarding our financial condition and
results  of  operations  should  be  read  in  conjunction  with  the  financial
statements  and related notes contained in Item 1 of Part I of this Form 10-QSB,
as  well as the financial statements in Item 7 of Part II of our Form 10-KSB for
the  fiscal  year  ended,  December  31,  2004.

MANAGEMENT'S  PLAN  OF  OPERATIONS

GENERAL  OVERVIEW


                                     - 14 -
<PAGE>
Zann  Corp.  has  four  principal  business  units:  biotechnology,  nutritional
supplements,  financial  services  and  semi-automatic  riveting  products.  Our
current  focus  is  increasing  production  and sales of semi-automatic riveting
products  based  on  our exclusive license to Sartam Industries, Inc.'s AutoFast
2000  technology.  We  recently  acquired  a  42.6%  interest in the outstanding
Common  Stock and 6.52% interest in the outstanding Convertible Preferred Second
Series  of Sartam Industries, Inc.  We are evaluating the long-term prospects of
our  biotechnology,  nutritional  supplements and financial services businesses,
and  we  may  consider  joint  ventures with respect to our biotechnology and/or
nutritional  supplements  businesses,  and  the  discontinuance of our financial
services  activities.

RECENT CHANGES IN OUR CORPORATE STRUCTURE

Effective  March  10,  2005,  we  implemented a one-for-350 reverse split of our
authorized,  issued  and  outstanding  shares  of  common  stock  by  filing  a
Certificate  of  Change  with  the  Secretary  of  State of Nevada (the "Reverse
Split").  Following  the  Reverse  Split, the number of authorized shares of our
common  stock was reduced to 11,428,572 in accordance with the one for 350 split
ratio.  The  number  of our authorized preferred shares remained at 350,000,000,
and the par value of our common and preferred stock remained at $0.001 per share
following  the  Reverse  Split.

All  fractional  shares  which  would  otherwise  be  held  by  our stockholders
following  the  Reverse  Split were rounded up to one whole share. We issued one
new  share  of common stock for up to each 350 shares of common stock held as of
March  9,  2005.

Effective  May  3,  2005,  we  implemented  a  three  for  one  forward split of
authorized,  issued  and  outstanding  shares  of  common  stock  by  filing  a
Certificate  of  Change  with  the  Secretary  of  State of Nevada (the "Forward
Split").  Following the Forward Split, the number of authorized shares of common
stock  was  increased  to  34,285,716 in accordance with the three for one split
ratio.  The  number  of authorized preferred shares remained at 350,000,000, and
the  par  value  of  common  and  preferred  stock  remained at $0.001 per share
following  the  Forward  Split.

The  Forward  Split  was a mandatory exchange. Our stockholders were required to
surrender  stock  certificates  representing their shares of our common stock in
order to receive stock certificates representing their post-Forward Split shares
of  the  Registrant's  common  stock.

Effective  May 9, 2005, we increased the number of authorized common shares from
34,285,716  to  4,000,000,000 by filing Articles of Amendment to our Articles of
Incorporation  with  the  Secretary of State of Nevada. The number of authorized
preferred  shares  remained  at  350,000,000,  and  the par value of common  and
preferred  stock  remained  at  $0.001  per share following the increase in  the
number  of  authorized  common  shares.

STRUCTURE

Semi-Automatic  Riveting
------------------------

We  hold  a  42.6%  interest  in  the  Common  Stock  and  6.52% interest in the
Convertible  Preferred  Second  Series of Sartam Industries, Inc., the holder of
approximately  30  patents  relating  to  the AutoFast 2000 technology.  We also
entered  into  an  exclusive  license  agreement with Sartam Industries, Inc. to
produce  and  sell  semi-automatic  riveting  products  world  wide based on the
AutoFast  2000  technology.  We  are  also  currently negotiating to acquire the
balance  of  Sartam  Industries, Inc. remaining capital stock.   We are building
tools and rivet magazines under the AutoFast(R) brand name. We shipped our first
products during the third quarter of 2005 and we plan to increase our production
capacity  and  commercialization  activities.  There is enormous interest in the
AutoFast(R)  products  and if all the inquiries turn to sales we will far exceed
our  sales  goals.

Biotechnology
-------------

The  research  of  our  biotechnology  division  resulted  in  the  discovery,
identification, and characterization of novel microbial agents. This bacterium's
working  title is "human blood-borne bacterium-1" (HBB1), and it is persistently
present  in  the  human bloodstream. The levels of HBB-1 appear to be associated
with  symptom  activity  in  Multiple  Sclerosis (MS) patients and with patients
suffering  from  other  disorders,  such  as  Chronic Fatigue Syndrome (CFS) and
certain  autoimmune  diseases.  It  has  taken  the  Company  several  years  to
characterize  this  organism  and  to  produce antibodies. We are evaluating the
prospects  of  these  antibodies and our options with respect to commercializing
related  products  and  may  consider  partnering  opportunities.


                                     - 15 -
<PAGE>
Nutritional  Supplements
------------------------

We  completed the acquisition of Blue Kiwi Inc. in the 3rd Quarter of 2004. Blue
Kiwi  is  a  nutraceutical company and currently has two products on the market,
the  Fatigue  Pack(R) and the PMS Pack(TM). Our new product development team has
developed prototypes for approximately 24 additional products. We are evaluating
the prospects of these additional products and our options with respect to their
commercialization,  as well as potential partnering strategies.

Financial  services  (development  stage)
-----------------------------------------

We have intended to facilitate mortgages working with existing mortgage brokers,
however,  in  view  of rising interest rates and other factors, we are currently
evaluating  whether  to  discontinue  this  business.

OBJECTIVES

Our  current  objectives  are  to:

     -    Raise  operating  capital  to  expand  production  and  manufacturing
          activities  with respect to our semi-automatic riveting products based
          on  the AutoFast 2000 technology we recently exclusively licensed from
          Sartam  Industries, Inc.;

     -    Evaluate  our  other  business  units  and  develop  plans  for
          commercializing  additional  products  ourselves,  with  partners,  or
          alternatively,  exiting  one  or  more  of  these  businesses

TECHNOLOGY  AND  PATENTS

We  exclusively  license the AutoFast 2000 technology used in our semi-automatic
riveting  products  from  Sartam  Industries, Inc. Sartam Industries, Inc. holds
approximately  30  patents  relating  to  this  technology.

We  hold  one patent relating to a blood-borne bacteria associated with multiple
sclerosis  and  chronic  fatigue syndrome, and one patent relating to activating
virus  associated  with  AIDS  and  several  cancers.  We  also  hold one patent
relating  to  compression  technology.

OVERVIEW

Zann  Corp.  has  four  principal  business  units:  biotechnology,  nutritional
supplements,  financial  services  and  semi-automatic  riveting  products.  Our
current  focus  is  increasing  production  and sales of semi-automatic riveting
products  based  on  our exclusive license to Sartam Industries, Inc.'s AutoFast
2000  technology.  We  recently  acquired  a  42.6%  interest in the outstanding
Common  Stock and 6.52% interest in the outstanding Convertible Preferred Second
Series  of Sartam Industries, Inc.  We are evaluating the long-term prospects of
our  biotechnology,  nutritional  supplements and financial services businesses,
and  we  may  consider  joint  ventures with respect to our biotechnology and/or
nutritional  supplements  businesses,  and  the  discontinuance of our financial
services  activities.

RESULTS OF OPERATIONS

CONTINUING OPERATIONS

REVENUE

NINE MONTHS ENDED SEPTEMBER 30, 2005 COMPARED TO THE NINE MONTHS ENDED SEPTEMBER
30, 2004.

Total  net  sales and revenues were $826 for the nine months ended September 30,
2005 compared to $505 for the period ended September 30, 2004, an increase of 64
percent.

Our gross profit (loss) for the nine months ended September 30, 2005 compared to
2004  decreased  to  $(417)  from  $505.  Gross  (loss) as a percentage of sales
increased  to  (50)  percent  in  2005  from  100  percent  in  2004.

Total  operating  expenses for the nine months ended September 30, 2005 compared
to  2004  decreased  by  $3,789,395  to  $1,849,888 from $5,639,283 in the prior
period.


                                     - 16 -
<PAGE>
Operating  loss  decreased from a loss of $5,638,778 to a loss of $1,850,305 for
the  nine months ended September 30, 2005 compared to the period ended September
30,  2004.

Interest  expense,  net  for the nine months ended September 30, 2005 was $9,956
as  compared  to  $12,835  for  the  same  period  of  2004.

Net loss from continuing operations for the nine months ended September 30, 2005
decreased to a loss of $1,860,260 from a loss of $5,331,761 compared to the same
period  2004

SETTLEMENT OF DEBTS AND LIABILITIES

We  have  continued  to pursue an active program to settle all outstanding debts
and  liabilities  from the predecessor company.  During the years ended December
31,  2004  and December 31, 2003,  a number of  debts  were  settled  by partial
payments  of  cash  or issuance  of Common or preferred Stock.  We will continue
to  pursue  the  same  course  during  2005.

LIQUIDITY AND CAPITAL RESOURCES

As  of September 30, 2005, we had a deficiency in working capital of $5,766,283.

     -    During  the  nine  months  ended  September  30,  2005  we  raised the
          following  amounts  for working capital: $100,000 through the issuance
          on  January  10, 2005 of a one year 10% Convertible Debenture, payable
          at  $1,000/month,  which  is  convertible  into  shares  of  Series  A
          Preferred  Stock at $.663 cents per share at the option of the holder;
     -    sold  14,192,327  shares  of  common  stock through the employee stock
          option  plan  for  $357,906;
     -    sold  267,001  shares  of  Preferred  Series  B  for $267,001 of which
          $117,001  had  been  collected by September 30, 2005 and the remaining
          $150,000  was  collected  in  October  2005.
     -    borrowed $225,000 on non-interest bearing promissory notes.

During the nine months ended September 30, 2005 we paid $9,956 in interest; made
$1,907  payments  on the principal balance of the Convertible Debenture and paid
$165,000  on  the  promissory  notes.

We used $200,000 in investing activities for the purchase of a subsidiary and no
capital  was  used  for  property,  plant,  and  equipment.

AUDITOR'S  OPINION  EXPRESSES DOUBT ABOUT THE COMPANY'S ABILITY TO CONTINUE AS A
"GOING  CONCERN"

The  independent  auditors  report on our December 31, 2004 financial statements
included  in  the  Company's  Annual Report states that the Company's historical
losses  and  the  lack  of revenues raise substantial doubts about the Company's
ability  to  continue  as  a  going  concern.  If  we  are unable to develop our
business,  we  have  to discontinue operations or cease to exist, which would be
detrimental  to  the  value  of  the  Company's  common  stock.  We  can make no
assurances  that  our  business  operations  will  develop  and  provide us with
significant  cash  to  continue  operations.

CRITICAL ACCOUNTING POLICIES

The  preparation  of  our  consolidated  financial statements in conformity with
accounting  principles  generally  accepted  in the United States requires us to
make  estimates  and  judgments  that  affect  our reported assets, liabilities,
revenues, and expenses, and the disclosure of contingent assets and liabilities.
We  base  our  estimates  and  judgments on historical experience and on various
other  assumptions  we  believe to be reasonable under the circumstances. Future
events,  however,  may  differ  markedly  from  our  current  expectations  and
assumptions.  While  there  are  a  number  of  significant  accounting policies
affecting  our  consolidated  financial  statements,  we  believe  the following
critical  accounting  policy  involve the most complex, difficult and subjective
estimates  and  judgments.

STOCK-BASED COMPENSATION

In  December  2002,  the  FASB  issued SFAS No. 148 - Accounting for Stock-Based
Compensation  - Transition and Disclosure.  This statement amends SFAS No. 123 -
Accounting  for  Stock-Based  Compensation,  providing  alternative  methods  of
voluntarily  transitioning  to  the fair market value based method of accounting
for  stock


                                     - 17 -
<PAGE>
based employee compensation. FAS 148 also requires disclosure of the method used
to account for stock-based employee compensation and the effect of the method in
both  the  annual  and  interim  financial  statements.  The  provisions of this
statement  related  to  transition methods are effective for fiscal years ending
after December 15, 2002, while provisions related to disclosure requirements are
effective  in financial reports for interim periods beginning after December 31,
2002. We elected to continue to account for stock-based compensation plans using
the  intrinsic  value-based  method  of  accounting  prescribed  by  APB No. 25,
"Accounting  for  Stock Issued to Employees," and related interpretations. Under
the provisions of APB No. 25, compensation expense is measured at the grant date
for  the  difference between the fair value of the stock and the exercise price.

On  December  16,  2004,  the Financial Accounting Standards Board (FASB) issued
FASB  Statement  No.  123R  (revised  2004),  "Share  Based  Payment" which is a
revision  of  FASB Statement No. 123, "Accounting for Stock-Based Compensation".
Statement  123R  supersedes  APB opinion No. 25, "Accounting for Stock Issued to
Employees",  and  amends  FASB  Statement  No.  95,  "Statement  of Cash Flows".
Generally,  the  approach in Statement 123R is similar to the approach described
in  Statement  123. However, Statement 123R requires all share-based payments to
employees,  including  grants of employee stock options, to be recognized in the
income  statement  based on their fair values. Pro-forma disclosure is no longer
an  alternative.  On  April  14, 2005, the SEC amended the effective date of the
provisions  of  this  statement. The effect of this amendment by the SEC is that
the Company will have to comply with Statement 123R and use the Fair Value based
method of accounting no later than the first quarter of 2006. Management has not
determined  the  impact  that this statement will have on Company's consolidated
financial  statements.

In March 2005, the FASB issued FASB Interpretation (FIN) No. 47, "Accounting for
Conditional  Asset  Retirement  Obligations, an interpretation of FASB Statement
No.  143,"  which requires an entity to recognize a liability for the fair value
of  a  conditional  asset retirement obligation when incurred if the liability's
fair  value  can  be  reasonably estimated. The Company is required to adopt the
provisions  of FIN 47 no later than its last quarter of fiscal 2006. The Company
does not expect the adoption of this Interpretation to have a material impact on
its  consolidated  financial  position,  results  of  operations  or cash flows.

In  May  2005 the FASB issued Statement of Financial Accounting Standards (SFAS)
No. 154, "Accounting Changes and Error Corrections, a replacement of APB Opinion
No. 20 and FASB Statement No. 3." SFAS 154 requires retrospective application to
prior  periods' financial statements for changes in accounting principle, unless
it  is  impracticable  to  determine  either  the period-specific effects or the
cumulative  effect  of  the  change.  SFAS  154 also requires that retrospective
application of a change in accounting principle be limited to the direct effects
of  the  change. Indirect effects of a change in accounting principle, such as a
change in non-discretionary profit-sharing payments resulting from an accounting
change,  should  be  recognized in the period of the accounting change. SFAS 154
also  requires  that a change in depreciation, amortization, or depletion method
for  long-lived, non-financial assets be accounted for as a change in accounting
estimate affected by a change in accounting principle. SFAS 154 is effective for
accounting  changes  and  corrections  of  errors made in fiscal years beginning
after  December 15, 2005. Early adoption is permitted for accounting changes and
corrections  of  errors  made  in  fiscal  years  beginning  after the date this
Statement  is  issued.  The Company does not expect the adoption of this SFAS to
have  a  material  impact  on  its  consolidated  financial position, results of
operations  or  cash  flows.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements.

INFLATION

In  the  opinion  of  management, inflation has not had a material effect on the
operations  of  the  Company.


ITEM 3.   CONTROLS AND PROCEDURES.

Disclosure  controls  and  procedures are controls and other procedures that are
designed  to  ensure  that  information  required  to  be disclosed by us in the
reports  that  we  file or submit under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the Securities and
Exchange  Commission's  rules  and  forms.  Disclosure  controls  and procedures
include,  without  limitation,  controls  and procedures designed to ensure that
information required to be disclosed by us in the reports that we file under the
Exchange  Act  is  accumulated and communicated to our management, including our
principal executive officers and principal financial officers, as appropriate to
allow  timely  decisions  regarding  required  disclosure.


                                     - 18 -
<PAGE>
Evaluation  of  Disclosure  and  Controls  and  Procedures. As of the end of the
period  covered  by this Quarterly Report, we conducted an evaluation, under the
supervision  and with the participation of our chief executive officer and chief
financial  officer,  of  our  disclosure  controls and procedures (as defined in
Rules  13a-15(e)  of  the  Exchange  Act).  Based  on this evaluation, our chief
executive  officer  and  chief  financial  officer concluded that our disclosure
controls  and procedures are effective to ensure that information required to be
disclosed  by  us  in  reports  that we file or submit under the Exchange Act is
recorded,  processed,  summarized and reported within the time periods specified
in  Securities  and  Exchange Commission rules and communicated to the Company's
management,  including  its  principal executive officer and principal financial
officer,  to  allow  timely  decisions  regarding  required  disclosure.

Changes  in  Internal  Controls over Financial Reporting. There was no change in
our  internal  controls  over  financial  reporting,  which  are included within
disclosure  controls  and  procedures, during our most recently completed fiscal
quarter  that  has  materially  affected,  or is reasonably likely to materially
affect,  our  internal  controls  over  financial  reporting.


PART II - OTHER INFORMATION

ITEM  1.   LEGAL PROCEEDINGS.

On  December  28, 2004, R. Patrick Liska filed a lawsuit in a Minnesota District
Court  asserting  claims against the Company and a third party.  The lawsuit has
since  been  transferred  to the United States District Court in Minnesota.  The
lawsuit  alleges  that  Mr.  Liska served as a director and Vice Chairman of the
Board of the Company in 2004.  The lawsuit seeks recovery of 1,000,000 shares of
the  Company's  Series  A Convertible Preferred stock, salary, vacation pay, and
various  business  expense  reimbursements.  Additionally,  the lawsuit  alleges
that  the  Company  was  engaged  in  a  joint enterprise with the third  party,
and  as  a  result,  the  Company is liable for any salary, vacation pay,  stock
grants,  or  expense  reimbursements  allegedly  due  and owing to Mr. Liska  by
the  third  party.  All  of  the  operative allegations in the lawsuit have been
denied  by  the  Company.

On  January 21, 2005, Plaintiff Investrend Communications, Inc. d/b/a Investrend
Research  commenced an action via Verified Complaint in the Supreme Court of the
State  of New York, County of Queens, against ATNG, Inc.  The complaint, through
three  causes of action, alleged a breach of contract.  Specifically, it alleged
that  ATNG, Inc. did not pay Plaintiff for providing news coverage of ATNG, Inc.
The parties have executed an agreement to settle the matter for the total amount
of  $7,500,  to  be  paid in six (6) installments.  The first installment was
paid  on  November  9,  2005.


ITEM  2.   UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Between  July  1, 2005 and September 30, 2005, the Company executed Subscription
Agreements  pursuant  to  which  several  private  investors received a total of
267,001  shares  of  Zann  Corp.  Preferred  Series  B  stock  in  exchange  for
$267,001.  The  $267,001  was  used  for  working  capital.

Each  share of the Series B preferred stock is convertible into one share of our
common  stock.  On  all matters submitted to a vote of the holders of our common
stock,  including,  without  limitation,  the election of directors, a holder of
shares  of  the  Series  B preferred stock is entitled to the number of votes on
such  matters equal to the number of shares of the Series B preferred stock held
by  such holder. The shares of the Series B preferred stock rank superior to the
shares  of  our  common  stock,  and  to  the  shares of all other series of our
preferred stock. The  shares  of  the  Series  B  Preferred stock were issued in
reliance  upon  an  exemption  from registration pursuant to Section 4(2) of the
Securities  Act.  All  of  the  investors  took  their securities for investment
purposes without a view to distribution and had access to information concerning
Zann Corp. and our business prospects, as required by the Securities Act.

In  addition,  there was no general solicitation or advertising for the purchase
of  our  shares.  Our  securities  were  sold only to persons with whom we had a
direct  personal  preexisting  relationship,  and  after  a thorough discussion.
Finally,  our  stock  transfer  agent has been instructed not to transfer any of
such  shares,  unless  such  shares  are  registered  for  resale or there is an
exemption  with  respect  to  their  transfer.


                                     - 19 -
<PAGE>
ITEM  3.  DEFAULTS  UPON  SENIOR  SECURITIES

None.


ITEM 4.   SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

None


ITEM 5.   OTHER INFORMATION.

     None.

<TABLE>
<CAPTION>
ITEM 6.   EXHIBITS.

EXHIBIT
   NO.                                             IDENTIFICATION OF EXHIBIT
   ---                                             -------------------------
<S>       <C>
2.1 (1)   Articles of Merger of Investra Enterprises, Inc. into Pathobiotek Diagnostics, Inc., a Texas corporation
          dated March 6, 2000.
2.2 (1)   Agreement and Plan of Reorganization by and among Pathobiotek Diagnostics Inc., a Texas corporation,
          and ATNG Inc., a Nevada corporation, dated August 24, 2001.
2.2 (2)   Plan and Agreement of Merger between ATNG, Inc. (TX) and ATNG of Nevada, Inc., dated September
          6, 2003.
2.3 (3)   Blue Kiwi Acquisition Agreement between Blue Kiwi, Inc., a Michigan corporation, and the Registrant
          dated August 10, 2004, as amended.
2.4 (4)   Sartam Stock Purchase Agreement by and between Robert C. Simpson or the Registrant as Nominee, and
          Charles Duke and Jonathon Derek Seltzer, dated June 27, 2005.
2.5 (4)   Sartam Contribution and Assumption Agreement by and among the Registrant and Robert Simpson, an
          individual, dated July 25, 2005.
3.1 (5)   Certificate of Amendment to Articles of Incorporation of the Registrant, effective May 3, 2005.
3.2       Bylaws of the Registrant, as amended September 6, 2003.
4.1 (1)   Certificate of Designation establishing the Registrant's Series A Preferred Stock, effective August 24,
          2004.
4.2 (1)   Certificate of Designation establishing the Registrant's Series B Preferred Stock, effective March 8, 2005.
4.3 (1)   Certificate of Designation establishing the Registrant's Series C Preferred Stock, effective March 21,
          2005, as amended.
10.1      Amended Promissory Note by and between the Registrant, Charles Duke and Jonathon Derek Seltzer
          dated August 1, 2005.
10.2      Exclusive Licensing Agreement by and between the Registrant and Sartam Industries, Inc., a Florida
          corporation, dated August 19, 2005.
31.1      Certification of Robert C. Simpson, President, Secretary, and Chairman of the Board of Directors of
          Zann Corp., pursuant to 18 U.S.C. Sec.1350, as adopted pursuant to Sec.302 of the Sarbanes-Oxley
          Act of 2002
31.2      Certification of George E. Betts, Chief Financial Officer of Zann Corp., pursuant to 18 U.S.C.  Sec.1350,
          as adopted pursuant to Sec.302 of the Sarbanes-Oxley Act of 2002
32.1      Certification of Robert C. Simpson, President, Secretary, and Chairman of the Board of Directors of Zann
          Corp., pursuant to 18 U.S.C. Sec.1350, as adopted pursuant to Sec.906 of the Sarbanes-Oxley Act of
          2002.
32.2      Certification of George E. Betts, Chief Financial Officer of Zann Corp., pursuant to 18 U.S.C.
          Sec.1350, as adopted pursuant to Sec.906 of the Sarbanes-Oxley Act of 2002
</TABLE>

_____
(1)  Incorporated by reference to the Registrant's Form 10-KSB as filed with the
     SEC  on  April  18,  2005.
(2)  Incorporated by reference to the Registrant's Form 14-A as filed with the
     SEC  on  August  18,  2003
(3)  Incorporated by reference to the Registrant's Form 8-K/A as filed with the
     SEC  on  May  3,  2005.
(4)  Incorporated by reference to the Registrant's Form 8-K as filed with the
     SEC  on  July  16,  2005.
(5)  Incorporated by reference to the Registrant's Form 8-K as filed with the
     SEC  on  June  22,  2005.


                                     - 20 -
<PAGE>
SIGNATURES

     In  accordance  with  the  requirements of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                        Zann Corp.
Dated: November 21, 2005
                                        By /s/ Robert C. Simpson
                                        ------------------------
                                        Robert C. Simpson, President and
                                        Chairman of the Board of Directors


                                     - 21 -